ASTAT+ coverage of drug metabolism AI competition results underscores a key lesson for pharmaceutical AI: predicting drug-body interactions tied to clearance sensors may not improve simply by scaling models. The piece focuses on pregnane X receptor (PXR), a regulatory hub that can trigger enzymes responsible for metabolizing roughly half of marketed drugs. The reporting highlights the operational bottleneck developers face today—PXR activation issues often get discovered late, forcing redesign and delays. AI tools that can forecast whether candidate compounds will activate PXR earlier could reduce late-stage failures and improve planning around drug-drug interaction and pharmacokinetic exit rates. For developers, the relevance is direct: a model that reliably anticipates PXR activation can compress the loop between chemistry iteration and safety assessment, improving throughput in discovery and early development.